CA2277970A1 - Composition pour l'administration transdermique de medicaments steroides - Google Patents

Composition pour l'administration transdermique de medicaments steroides Download PDF

Info

Publication number
CA2277970A1
CA2277970A1 CA002277970A CA2277970A CA2277970A1 CA 2277970 A1 CA2277970 A1 CA 2277970A1 CA 002277970 A CA002277970 A CA 002277970A CA 2277970 A CA2277970 A CA 2277970A CA 2277970 A1 CA2277970 A1 CA 2277970A1
Authority
CA
Canada
Prior art keywords
composition
drug
diethylene glycol
ranges
absorption promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002277970A
Other languages
English (en)
Inventor
Cheol Moon
Jong-Kun Choi
Mi-Suk Choi
Je-Phil Ryoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2277970A1 publication Critical patent/CA2277970A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne une composition pour l'administration transdermique d'un médicament stéroïde, contenant une dose thérapeutiquement efficace dudit médicament. Elle porte aussi sur un agent promoteur d'absorption consistant essentiellement en un éther de diéthylène glycol et en un ester de sorbitanne, ainsi que sur une matrice adhésive pharmaceutiquement acceptable.
CA002277970A 1997-01-27 1998-01-23 Composition pour l'administration transdermique de medicaments steroides Abandoned CA2277970A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1019970002233A KR100215027B1 (ko) 1997-01-27 1997-01-27 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형
KR1997-2233 1997-01-27
PCT/KR1998/000013 WO1998032465A1 (fr) 1997-01-27 1998-01-23 Composition pour l'administration transdermique de medicaments steroides

Publications (1)

Publication Number Publication Date
CA2277970A1 true CA2277970A1 (fr) 1998-07-30

Family

ID=19495561

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002277970A Abandoned CA2277970A1 (fr) 1997-01-27 1998-01-23 Composition pour l'administration transdermique de medicaments steroides

Country Status (12)

Country Link
EP (1) EP1001812A1 (fr)
JP (1) JP2000508349A (fr)
KR (1) KR100215027B1 (fr)
CN (1) CN1244806A (fr)
AR (1) AR011577A1 (fr)
AU (1) AU727811B2 (fr)
BR (1) BR9807009A (fr)
CA (1) CA2277970A1 (fr)
ID (1) ID19755A (fr)
RU (1) RU2176499C2 (fr)
TW (1) TW537899B (fr)
WO (1) WO1998032465A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100294084B1 (ko) * 1998-06-02 2001-09-22 성재갑 비-스테로이드성소염진통제의경피흡수투여용조성물및이를포함하는경피흡수투여용제형
WO2000040230A2 (fr) * 1999-01-06 2000-07-13 Cedars-Sinai Medical Center Substitution d'un hormone chez les patientes souffrant du cancer du sein
KR100403051B1 (ko) * 2000-07-25 2003-10-23 일양약품주식회사 음낭 외 피부에 적용가능한 남성호르몬 경피흡수 패취제
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10107663B4 (de) * 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
FR2848112B1 (fr) * 2002-12-10 2007-02-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
AU2003296810A1 (en) * 2002-12-10 2004-07-09 Besins International Belgique Pharmaceutical composition for transdermal or transmucous administration comprising a progestin or an estrogen, method for preparing same and uses thereof
FR2851470B1 (fr) 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
JP4422430B2 (ja) * 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び/又はプロゲストゲン含有外用貼付剤
US20070231373A1 (en) * 2004-04-28 2007-10-04 Hunter-Fleming Limited Transdermal Steriod for Formulation
CN1313084C (zh) * 2004-11-05 2007-05-02 郑会义 一种透皮避孕药传送体系及制备方法
DE102004059880A1 (de) * 2004-12-10 2006-06-14 Grünenthal GmbH Stabiles, hormonhaltiges (Zwischen-)Produkt
JP2007045808A (ja) * 2005-01-07 2007-02-22 Rohto Pharmaceut Co Ltd 皮膚外用剤
JP4969050B2 (ja) * 2005-01-07 2012-07-04 ロート製薬株式会社 皮膚外用剤
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
WO2013054809A1 (fr) * 2011-10-14 2013-04-18 大正製薬株式会社 Préparation externe pour la peau
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP5521025B2 (ja) * 2012-12-21 2014-06-11 日本精化株式会社 浸透促進剤
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR101968873B1 (ko) * 2018-09-21 2019-04-29 아이큐어 주식회사 세포 침투 효과가 우수한 보툴리늄 유래 펩타이드를 포함하는 화장료 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
JPH0744940B2 (ja) * 1986-12-24 1995-05-17 ライオン株式会社 口腔貼付用基材
CH674618A5 (fr) * 1987-04-02 1990-06-29 Ciba Geigy Ag
CA1333114C (fr) * 1987-11-25 1994-11-15 Daniel C. Duan Adhesifs baronsensibles et bio-electrodes fabriquees avec ces adhesifs
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
HU210549B (en) * 1988-10-27 1995-05-29 Schering Ag Process for producing transdermally applicable pharmaceutical composition containing gestodene
DE3910578A1 (de) * 1989-03-29 1990-10-04 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
DE69010076T2 (de) * 1989-05-25 1994-12-08 Takeda Chemical Industries Ltd Transdermales therapeutisches Mittel.
US5314685A (en) * 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents

Also Published As

Publication number Publication date
ID19755A (id) 1998-07-30
BR9807009A (pt) 2000-03-14
RU2176499C2 (ru) 2001-12-10
JP2000508349A (ja) 2000-07-04
KR19980066583A (ko) 1998-10-15
AU727811B2 (en) 2000-12-21
AR011577A1 (es) 2000-08-30
AU5882098A (en) 1998-08-18
KR100215027B1 (ko) 1999-08-16
WO1998032465A1 (fr) 1998-07-30
EP1001812A1 (fr) 2000-05-24
CN1244806A (zh) 2000-02-16
TW537899B (en) 2003-06-21

Similar Documents

Publication Publication Date Title
AU727811B2 (en) Composition for the transdermal administration of steroid drugs
US20010023261A1 (en) Novel composition for the transdermal administration of drugs
US9005653B2 (en) Transdermal delivery of hormones with low concentration of penetration enhancers
CA2183543C (fr) Systemes therapeutiques transdermiques contenant des steroides sexuels
US5554381A (en) Low flux matrix system for delivering potent drugs transdermally
JP2001508070A (ja) ホルモン剤供給のための経皮吸収治療システム
SK280493B6 (sk) Samolepiaca náplasť na transdermálnu aplikáciu sys
CN1596105A (zh) 含有甾类激素和含有丙二醇单辛酸酯的透皮治疗系统
EP2138169B1 (fr) Système d'administration transdermique d'hormones sans promoteurs de pénétration
WO1999062557A1 (fr) Composition destinee a une administration transdermique de medicaments anti-inflammatoires non steroidiens
CA2549916C (fr) Administration transdermique d'hormones sans utilisation d'un agent facilitant la penetration
MXPA99006959A (en) Composition for the transdermal administration of steroid drugs
KR960013236B1 (ko) 에스트로겐/프로게스틴 경피 전달 장치 및 이를 포함하는 키트
US8671945B2 (en) Low-dose transdermal patches with high drug release
HK1074801B (en) Transdermal delivery system of gestodene
HK1132682B (en) Transdermal delivery system of hormones without penetration enhancers

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead